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• Most patients with established coronary artery disease have suboptimal lipid management.• More professional strategies are needed aiming at lifestyle changes and LLT adapted to the need of the individual patient.• The striking variability between countries and centers with several examples of well managed patients illustrates that the present conditions can be improved.
A R T I C L E I N F O
Keywords:
LDL-Cholesterol
Coronary heart disease
EUROASPIRE
Secondary prevention
Dyslipidaemia
Lipid lowering therapy
A B S T R A C T
Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well
European guidelines on the management of dyslipidaemias are implemented in coronary patients.
Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from
130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a
coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into
three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no
LLT.
Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital
discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been
started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity,
intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the
cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or
moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes.
Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal
management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to
the need of the individual patient.
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1. Introduction
Despite significant progress in secondary prevention of coronary
heart disease (CHD) over the past decades, the incidence of recurrent
events remains a problem for many patients and the society. In a
Swedish national registry with more than 100,000 patients, post acute
myocardial infarction (AMI) recurrent events were observed in 18% of
the cohort during the first year following the index event and in 20%
during the following three years among those who remained free of
recurrent events during the first year [1].
The consequences are high numbers of premature mortality, of
disability adjusted life years (DALYs) and of avoidable health care costs.
More efforts to improve secondary prevention of CHD are needed.
Evidence that an efficient risk factor control has great potential in
avoiding unnecessary cardiovascular events has recently been docu-
mented in a large Swedish cohort study [2].
The European Society of Cardiology has since 1994 a comprehen-
sive program of cardiovascular disease (CVD) prevention by developing
and updating guidelines and implementation strategies. All this is
regularly evaluated through the European Society of Cardiology –
Eurobservational Research Programme (ESC-EORP) EUROASPIRE
(European Action on Secondary and Primary Prevention by
Intervention to Reduce Events) surveys. The EUROASPIRE IV survey
incorporated the EuroHeart Survey on Diabetes to create the first
European Survey of CVD prevention and diabetes. The aim of the pre-
vention guidelines and the results from the EUROASPIRE I-IV surveys
have been extensively communicated [3–16]. The most recent survey
(EUROASPIRE V) in coronary patients took place in 2016–17 in 27
countries and the overall results have been reported [17].
In recent guidelines on CVD prevention in clinical practice [8] it is
recommended to treat all patients with established CHD using lifestyle
changes and cardio-protective drug therapies. Regarding the control of
dyslipidaemia, achieving a low-density-lipoprotein cholesterol (LDL-C)
level of< 1.8mmol/L (70mg/dL) is recommended or a reduction of at
least 50% if the baseline LDL-C level is between 1.8 and 3.5mmol/L
(70–135mg/dL). Non-HDL-cholesterol (Non-HDL-C) is regarded as a
secondary target with a treatment goal of< 2.6mmol/L (100mg/dL).
Trials have provided evidence that high-intensity LDL-C-lowering drug
therapies (LLT) are more effective than low-intensity LLT at reducing
recurrent events in coronary patients [18–20]. In an observational
study a graded association was observed between the intensity of statin
therapy and total mortality in patients with atherosclerotic CVD [21].
The safety and efficacy of the use of high-intensity LLT to achieve low
levels of LDL-C in patients with CHD has been well documented [22].
The objectives of this report is to describe the lipid profile of cor-
onary patients from 27 countries, the management of elevated LDL-C
levels, the change that occurred in LLT between hospital discharge and
what was actually taken at the time of the interview. Reasons for re-
ducing the dosage or for stopping the LLT were enquired as well.
Finally, the management of dyslipidaemia in these coronary patients
was looked after according to patient characteristics.
2. Materials and methods
The hospital arm of the EUROASPIRE V surveys patients with
documented CHD. National coordinators of 27 countries (Belgium,
Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Egypt,
Finland, Germany, Greece, Ireland, Italy, Kazakhstan, Kyrgyzstan,
Latvia, Lithuania, the Netherlands, Poland, Portugal, Romania, Russian
Federation, Serbia, Slovenia, Spain, Sweden, Turkey, Ukraine and the
United Kingdom) identified within their country one to three geo-
graphical areas, each with a population of at least half a million in-
habitants. Within these areas, hospitals were identified in which pa-
tients with CHD were hospitalized. The number of geographical areas
depended on the country size. In each participating hospital con-
secutive patients aged> 18 and < 80 years, who had been
hospitalized at least 6 months and at most 2 years prior to the scheduled
interview, were identified. The reason for hospitalization was an elec-
tive CABG, an elective PCI or an acute coronary syndrome (ACS). The
eligible patients were invited for an interview and in those who parti-
cipated, some information from the medical records was retrieved.
Participants were seen by centrally trained research technicians
who used standardized methods to collect information through ques-
tionnaires and interviews among which questions on adopted lifestyle
changes since the hospital stay and on the actual use of and adherence
to lipid lowering drugs (generic name and total daily dosage). They also
measured blood pressure, body weight and height and breath CO with
similar instruments in all centers. High-intensity LDL-lowering thera-
pies were defined as daily dosages that are on average associated with a
reduction of LDL-C of at least 50%. All other lipid lowering drug
therapies were considered as of ‘low or intermediate intensity’.
Venous blood samples were taken after an overnight fast in the
sitting position with light stasis into a tube containing clot activator
(Vacutainer SST II Advanced, Becton Dickinson) for lipid assays. Serum
was separated by centrifuging at 2000 g for 10min at room tempera-
ture. After that serum was aliquoted into 2 bar-code-labelled tubes and
stored locally at a minimum of −70 °C and then transported frozen to
the central laboratory (Biochemistry Laboratory, National Institute for
Health and Welfare, Helsinki, Finland) where all measurements were
performed on a clinical chemistry analyzer (Architect c8000; Abbott
Laboratories, Abbott Park, Illinois, USA). Total cholesterol (TC), HDL-
cholesterol (HDL-C) and triglycerides (TG) were analysed in serum,
with the following methods: enzymatic methods for total cholesterol
and triglycerides and a homogenous method for direct measurement of
HDL cholesterol. Non-HDL-C was calculated as TC-(HDL-C) and LDL-C
using the Friedewald formula in patients with fasting TG < 4.5mmol/
L (400mg/dL). The laboratory takes part in Lipid Standardization
Program organized by CDC, Atlanta, Georgia, USA and External Quality
Assessment Schemes organized by Labquality, Helsinki, Finland and is
accredited by the Finnish Accreditation Service. It fulfils the require-
ments of the standard SFS-EN ISO/IEC 17025:2005. During the course
of the study, comprising four months in 2017, the coefficient of varia-
tion (mean ± SD) and systematic error (bias) (mean ± SD) were
1.2% ± 0.1 and 0.0% ± 1.0 for total cholesterol, 1.9% ± 0.5 and
−0.1% ± 2.4 for HDL cholesterol, 1.3% ± 0.2 and −1.8% ± 2.0 for
triglycerides, respectively.
In the large majority of the patients the untreated baseline LDL-C
level was not known; therefore it was not possible to calculate the %
reduction from baseline and the LDL-C goal was set for all patients
at< 1.8mmol/L (70mg/dL).
Height and weight were measured in light indoor clothes without
shoes using SECA scales 701 and measuring stick model 220. Obesity
was defined as a BMI ≥30 kg/m2. Smoking at the time of interview was
defined as self-reported smoking, and/or a breath carbon monoxide
(CO) exceeding 10 ppm; breath CO was measured using a Smokerlyser
device (Micro + Bedfont Scientific, UK). Regular physical activity was
defined as physical activity of at least 30 min duration on average 5
times a week. Low educational level was defined as ‘no formal
schooling, less than primary school or primary school completed’.
2.1. Data management
Data management was undertaken by the EORP at the European
Heart House, Sophia-Antipolis, France. All data were collected elec-
tronically through web based data entry using a unique identification
number for country, centre and individual. The data were submitted via
the Internet to the data management centre where checks for com-
pleteness, internal consistency and accuracy were run. All data were
stored under the provisions of the National Data Protection Regulations.
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2.2. Statistical analyses
Descriptive statistics (mean, standard deviation, median, inter-
quartile range, proportion) were used to describe patient character-
istics, lipid profiles, dietary changes and the use of lipid-lowering drug
therapies. The association between patient characteristics and the
therapeutic control of lipids was statistically evaluated according to
mixed logistic modelling, the latter accounting for the clustering of
patients within centers. A two-sided p < 0.05 was considered as in-
dicating statistical significance. All data analyses were undertaken
using SAS statistical software release 9.4 (SAS Institute Inc., Cary, North
Carolina, USA) at the Department of Public Health, Ghent University,
Belgium.
2.3. Ethical procedures
National coordinators were responsible for obtaining Local Research
Ethics Committees approvals. Written, informed consent was obtained
from each participant by the investigator by a signed declaration. The
research assistants signed in the Case Record Form verifying that in-
formed consent was obtained. The original signed declaration consent
was stored in the patient file.
3. Results
Overall 16,208 patients were identified from consecutive lists of
hospitalized patients of whom 8261 (56%) took part in the interview.
For the purpose of this analysis on the management of dyslipidaemia
full results were available in 7824 patients from 130 centers in 27
countries. They were on average 63.6 years of age (SD: 9.6 years) and
25.7% were females. Smoking was prevalent in 18.5% of these patients;
38% were obese and 35% did not engage in regular physical activity.
The median time between hospital discharge and interview was 1.12
years (P25-P75 0.82–1.57 years).
In Table 1, the lipid profile is presented according to gender and age
at interview. The lipid profile was on average less optimal in women
compared to men with higher levels of TC, LDL-C and non-HDL-C. The
proportion with low HDL-C levels was higher in women compared to
men. The lipid profile was on average less optimal in young compared
to older patients. These lipid profiles are given across the participating
countries in Supplementary Table 1, illustrating the large heterogeneity
between countries in the proportions with elevated TC, LDL-C and non-
HDL-C. The differences in residual risk related to low HDL-C and high
TG were also very large between countries. There were also consider-
able differences in the lipid profile between patients from different
centers within a given country; for instance in country X the prevalence
of LDL-C<1.8mmol/L (70mg/dL) in patients on LLT was 24% in
centre A and 41% in centre B.
In Table 2, the proportions of the patients on lipid lowering drugs at
the interview are given according to gender and age. Almost half of the
patients (n= 3811) were on a high-intensity LLT (men=51.3%;
women=46.0%). The high-intensity LLT related in 72% to atorvas-
tatin 40–80mg/d and in 20% to rosuvastatin 20–40mg/d while 8%
were on combinations of statins with ezetimibe. Only 15 patients (0.4%
of all those on high-intensity LLT) from 7 different countries were
treated with PCSK9 inhibitors with or without statins and/or ezetimibe.
The combination of atorvastatin 40–80mg/d or rosuvastatin
20–40mg/d with ezetimibe 10mg/d was reported by 211 patients
(5.5% of all those on a high-intensity LLT and 2.7% of all patients); in
them the LDL-C goal of< 1.8mmol/L (70mg/dL) was achieved in
52%.
On the question “how often they took their lipid lowering drugs as
prescribed by their doctor”, 92% answered all or nearly all of the time,
a proportion that varied between countries from 70 to 98%.
In Supplementary Table 2, the use of LLT is presented across par-
ticipating countries illustrating a large variation with high-intensity LLT
used in>80% of the patients in some countries compared to< 10% in
other countries.
Changes in LLT between what was prescribed at hospital discharge
to what was actually used at the visit are presented in Table 3. There
were no changes in 67.5% and in this group 5% were never on a LLT,
20.2% remained on a low/moderate intensity LLT and 42.3% on a high-
Table 1
Lipid profile according to gender and age at interview.
TC≥4.5mmol/L HDL-C < 1.0/1.2 mmol/L for men/women Non-HDL-C ≥ 2.6mmol/L TG≥1.7mmol/L LDL-C ≥ 1.8mmol/L LDL-C ≥ 2.6mmol/L
% (n) % (n) % (n) % (n) % (n) % (n)
All 35.5 (2780/7824) 40.8 (3194/7824) 63.3 (4953/7824) 33.3 (2450/7351) 71.0 (5375/7575) 33.4 (2531/7575)
Men 31.5 (1831/5813) 38.7 (2251/5813) 60.4 (3512/5813) 32.5 (1767/5443) 68.6 (3853/5620) 30.4 (1707/5620)
Women 47.2 (949/2011) 46.9 (943/2011) 71.7 (1441/2011) 35.8 (683/1908) 77.9 (1522/1955) 42.2 (824/1955)
Age < 50 yrs 37.2 (271/729) 51.3 (374/729) 67.6 (493/729) 41.0 (286/697) 72.7 (499/686) 36.0 (247/686)
Age 50–59 yrs 36.5 (697/1911) 45.4 (868/1911) 66.7 (1275/1911) 37.9 (679/1792) 72.6 (1327/1827) 36.0 (658/1827)
Age 60–69 yrs 36.6 (1096/2992) 40.9 (1225/2992) 63.9 (1913/2992) 35.0 (983/2812) 71.4 (2079/2911) 33.8 (985/2911)
Age≥ 70 yrs 32.7 (716/2192) 33.2 (727/2192) 58.0 (1272/2192) 24.5 (502/2050) 68.3 (1470/2151) 29.8 (641/2151)
Table 2
LDL-C lowering drug therapies according to gender and age at interview.
LDL-C lowering therapy, % (n)
All Low or moderate intensity High intensity
All 84.3 (6514/7732) 34.1 (2603/7632) 49.9 (3811/7632)
Men 85.6 (4920/5746) 34.1 (1935/5671) 51.3 (2910/5671)
Women 80.3 (1594/1986) 34.1 (668/1961) 46.0 (901/1961)
Age < 50 yrs 80.4 (580/721) 28.7 (205/715) 51.6 (369/715)
Age 50–59 yrs 84.4 (1593/1888) 32.3 (601/1860) 51.8 (964/1860)
Age 60–69 yrs 83.6 (2472/2958) 33.5 (979/2921) 49.8 (1456/2921)
Age≥ 70 yrs 86.3 (1869/2165) 38.3 (818/2136) 47.8 (1022/2136)
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intensity LLT. The LLT was reduced in intensity in 10.0% of the patients
and completely interrupted in another 10.8% while LLT was initiated in
7.1% and increased in intensity among 4.6%.
In patients who reported a change from high-intensity LLT to low/
moderate intensity LLT or from any LLT to no LLT, intolerance to statins
was given as the main reason (15.8%). Another 36.8% reported that the
change was based on the advice of their physician without any detailed
explanation. A refusal to take statins was reported by another 14.3%
and 33.1% had other reasons or was unsure of the reason of the change.
In those who reported statin intolerance muscular pain was reported as
the main symptom (62%) while non-muscular adverse events occurred
in 14%, other adverse effects in 21% and 3% were uncertain.
The control of LDL-C is presented in Table 4 for two different
treatment targets (< 1.8 and < 2.6mmol/L [< 70 and < 100mg/
dL]) as well as for non-HDL-C at < 2.6 and < 3.4mmol/L (< 100
and < 130mg/dL) according to different patient characteristics.
Lipid control seemed to be better in men than in women and im-
proved somewhat by increasing age and with higher education. There
was no relation between LDL-C control and BMI categories or physical
activity while smoking was systematically associated with unfavorable
lipid levels. In patients with self-reported diabetes LDL-C and to a lesser
extent non-HDL-C were better controlled. Both lipid fractions were
better controlled in patients on LLT compared to those not on LLT and
the control was better in those on high-intensity LLT than those on low/
moderate LLT.
In Fig. 1, a comparison is made between patients at goal for LDL-C
and those not at goal with respect to other lipid fractions that influence
the residual risk of recurrent events: 9.4% of the patients who were at
goal for LDL-C were not at goal for non-HDL-C while 30% of those at
goal for non-HDL-C were not at goal for LDL-C. A low HDL-C was more
Table 3
Change in the LDL-C-lowering therapies from discharge to interview.
Prescribed at hospital discharge Used at the time of interview % (n)
No LLT No LLT 5.0 (374/7528)
Low/Moderate intensity LLT Low/Moderate intensity LLT 20.2 (1521/7528)
High intensity LLT High intensity LLT 42.3 (3181/7528)
High intensity LLT Low/Moderate intensity LLT 10.0 (755/7528)
High intensity LLT No LLT 6.2 (463/7528)
Low/moderate intensity LLT No LLT 4.6 (350/7528)
No LLT Low/moderate intensity LLT 3.9 (297/7528)
No LLT High intensity LLT 3.2 (241/7528)
Low/moderate intensity LLT High intensity LLT 4.6 (346/7528)
LLT: LDL-C-lowering therapies.
Table 4
Lipid control according to patient characteristics.
Lipid control, % (n)
LDL-C < 1.8mmol/L LDL-C < 2.6mmol/L Non-HDL-C < 2.6mmol/L Non-HDL-C < 3.4mmol/L
Men 32.3 (1561/4835) 69.6 (3913/5620) 39.6 (2301/5813) 71.6 (3577/4999)
Women 23.1 (377/1635) 57.8 (1131/1955) 28.3 (570/2011) 61.7 (1036/1679)
Age < 50 yrs 27.7 (165/596) 64.0 (439/686) 32.4 (236/729) 63.3 (400/632)
Age 50–59 yrs 28.5 (436/1531) 64.0 (1169/1827) 33.3 (636/1911) 66.2 (1061/1602)
Age 60–69 yrs 29.9 (737/2465) 66.2 (1926/2911) 36.1 (1079/2992) 68.9 (1744/2531)
Age≥ 70 yrs 31.9 (600/1878) 70.2 (1510/2151) 42.0 (920/2192) 73.6 (1408/1913)
Low educational levela 33.9 (323/954) 72.7 (800/1101) 41.0 (465/1133) 73.8 (725/982)
Higher educational level 29.3 (1615/5516) 65.8 (4180/6353) 36.2 (2378/6560) 68.3 (3888/5696)
BMI < 25 kg/m2 28.1 (349/1240) 65.2 (917/1407) 41.7 (595/1426) 70.8 (889/1255)
BMI 25–29.9 kg/m2 29.5 (843/2856) 67.8 (2230/3290) 37.8 (1279/3384)d 70.1 (2061/2939)
BMI≥30 kg/m2 31.4 (746/2374) 66.1 (1844/2790) 33.3 (971/2918)f 66.9 (1663/2484)
Not currently smoking 31.0 (1655/5340) 67.9 (4211/6198) 38.4 (2447/6377) 70.9 (3891/5491)
Currently smokingb 25.0 (283/1130)e 60.5 (833/1377)c 29.3 (424/1447)f 60.8 (722/1187)f
Physical activity on targetc 31.3 (712/2274) 66.5 (2981/4484) 36.0 (1664/4628) 72.1 (1692/2347)
Physical activity not on targetc 29.2 (1226/4196) 72.0 (1709/2374) 42.1 (1032/2451) 67.4 (2921/4331)
No self-reported diabetes 26.3 (1234/4691) 64.9 (3503/5395) 35.9 (1980/5515) 68.7 (3293/4794)
Self-reported diabetes 39.6 (704/1779)f 70.8 (1496/2114)f 38.6 (866/2243) 70.1 (1320/1884)
No LLT 13.9 (126/907) 32.1 (373/1162) 15.4 (188/1218) 36.6 (348/950)
Low/moderate LLT+ 26.3 (573/2178)f 66.9 (1688/2524)f 33.5 (872/2603)f 69.1 (1550/2242)f
High intensity LLT+ 36.6 (1239/3385)f 77.2 (2857/3701)f 45.2 (1724/3811)f 77.9 (2715/3486)f
a 'No formal schooling’, ‘Less than primary school’ or ‘Primary school completed’.
b Self-reported smoking or CO in breath > 10 ppm.
c Regular physical activity of at least 30 min duration on average 5 times a week; +LLT = LDL-C lowering drug therapies.
d p < 0.01.
e p < 0.001.
f p < 0.0001 (after adjustment for gender and age at interview and taking clustering of patients within centers into account).
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frequently observed in patients at goal for LDL-C compared to the group
not at goal for LDL-C and the reverse was true for elevated TG.
4. Discussion
The EUROASPIRE V survey clearly shows that the overall lipid
control was unsatisfactory in a large proportion of patients as reflected
by elevated levels of TC, LDL-C, non-HDL-C and TG and low levels of
HDL-C. Unfortunately, other fractions such as apo B and Lp(a) were not
measured. This situation was on average worse in women and in young
patients. Moreover, there was a substantial variation in these lipid
profiles between patients from different participating countries and
between patients from different centers within a country; this illustrates
that it is possible to achieve targets and that standard of care is an
important factor.
4.1. Lifestyle related issues
The causes of the poor adherence to guideline recommended man-
agement are multiple. An optimal control of dyslipidaemia requires
both lifestyle changes and LLT adapted to individual demands. Given
the international, multicenter design of EUROASPIRE V it was not
possible to organize a full quantitative dietary survey. A high quality
diet is essential in secondary prevention not only for LDL-C control as
documented in patients with CAD in the Nurses’ Health study and the
Health Professionals Follow-up study [23] as well as in the OASIS-5
trial [24]. Residual risk reduction in patients with CHD can also be
achieved with smoking cessation and with regular physical exercise
[25,26]. These lifestyles were poorly adapted in the patients of EUR-
OASPIRE V [17].
4.2. Lipid lowering drugs
Present recommendations advocate, irrespective of the LDL-C level,
prescription of LLT to all patients with documented CHD if not con-
traindicated. In EUROASPIRE V an average of 84% of all patients were
on LLT, varying between the 27 countries from 75 to 98%. The corre-
sponding average proportions were 80% (varying from 38 to 92%) in
EUROASPIRE III (22 countries; 2006–7) and 86% (varying from 72 to
97%) in EUROASPIRE IV (24 countries; 2012–13) [12,27].
The results of EUROASPIRE V may be considered as ‘real life data’
reflecting contemporary practice in contrast with observations in clin-
ical trials presenting patient populations subjected to selection bias and
strict control of drug intake.
The present findings are unfortunately not unique. In the STABILITY
trial [28] 97% of 15 828 patients with stable CHD from 39 countries on
five continents were on statins and 29% of them had a LDL-
C > 2.5mmol/L. This should be compared with 84% on LLT and 33%
at a LDL-C 2.6mmol/L in EUROASPIRE V. In similarity with EURO-
ASPIRE V regional results in STABILITY differed considerably sug-
gesting that other factors such as lifestyle, prescription inertia, in-
sufficient drug dosage and patient compliance are important. In a
retrospective examination of LLT in a real world cohort performed in
2014 in the United Kingdom, 79% of 91 470 patients with athero-
sclerotic CVD (mean age 73 years) received statin treatment whereof
31% atorvastatin 80mg o.d. or the equivalent. A total of 31% had a
LDL-C<1.8mmol/L (70mg/dL) and 12% a non-HDL-C of< 2.6
mmol/L (100mg/dL) [29]. The SURF survey included 10 186 patients
with CHD (29% women) from 79 centers in 11 countries. One fifth were
not taking any LLT therapy and only 30% reached a LDL-C<70mg/dL
(< 1.8mmol/L) [30].
In the DYSIS study, 10,587 statin-treated patients with CVD were
selected in 2008–9 in 11 Western-European countries and in Canada.
LDL-C was< 2.5mmol/L (100mg/dL) in 58%. High potency statins
(equivalent to 80–160mg/d of simvastatin) was used by 14% of all
high-risk patients. Importantly, higher statin dose was the single
greatest modifiable predictor of LDL-C at goal. In these statin-treated
patients a low HDL-C (< 1.0mmol/L [39mg/dL] in men and< 1.2
mmol/L [46mg/dL] in women) was found in 31% and elevated TG (
1.7 mmol/L [ 150mg/dL]) in 39% [31]. In the International Choles-
terol Management Practice Study (ICLPS) in 18 countries outside
Western-Europe 4842 patients at very-high cardiovascular risk and on a
stable lipid lowering therapy were enrolled in 2015–16. Almost all of
them were on statins with 33% on high-intensity statins. A total of 32%
of all these very-high risk patients achieved a LDL-C of< 1.8mmol/L
(70mg/dL) [32]. The uniform experience from these trials and most
recently from the EUROASPIRE V survey is that considerable efforts
should be invested in improving lipid management in patients with
coronary artery disease manifestations.
More potent statins reduce morbidity and mortality after an acute
myocardial infarction (AMI) more effectively than less potent statins
[18,33–35]. This is reflected in the 2011 and the 2016 EAS/ESC
guidelines for the management of dyslipidaemia [36,37]. Both re-
commend that high dose statins should be initiated early after admis-
sion in all patients with acute coronary syndrome without contra-
indications or a history of intolerance regardless of the LDL-C value. In
EUROASPIRE V 88% of all patients were discharged on LLT whereof
59% on high-intensity treatment. Of 4340 US patients hospitalized for
an AMI 2005–8 in the TRIUMPH study 87% of 2776 statin naïve pa-
tients were prescribed a statin and among patients who arrived on a
Fig. 1. Elevated non-HDL-C and TG and low HDL-C levels in patients at goal or not at goal for LDL-C.
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submaximal statin dose 26% had their therapy intensified. Only 140
were on a maximal dose at entry. Among all patients without a con-
traindication 23% were discharged on maximal statin therapy but there
was a large in between hospitals variability in this respect [38].
In patients at extremely high CVD risk it is recommended to reduce
LDL-C by at least 50% or towards even lower targets than<1.8mmol/
L (70mg/dL) [39,40]. If that can not be achieved with maximally tol-
erated high-intensity statins alone it is recommended to add ezetimibe
and, if needed, a PCSK9 inhibitor. In EUROASPIRE V only 55% of all
participants were discharged on a high-intensity statin and at interview
only 2.7% were on a combination of a high-intensity statin with eze-
timibe. It is clear that substantial improvements can be achieved by an
up titration of statin therapy and by using combined LLT in a large
proportion of patients with CVD.
PCSK9 inhibitors were used in only 15 patients from 7 countries in
EUROASPIRE V. This relates probably to the fact that in 2016–17 the
availability of these drugs was limited. Even in early 2019 only 14 of
the 27 EUROASPIRE V countries had access to these drugs. The efficacy
of PCSK9 inhibitors has been demonstrated [19,20] but the high cost,
based on the 2018 prices, remains a barrier to its clinical application.
In addition, results from the REDUCE-IT trial do suggest that low-
ering of other lipid components may improve outcomes in selected
groups of patients [41].
4.3. Gender and age
An important finding in EUROASPIRE V is that women were less
treated with LLT and less often received high-intensity LLT than men.
This was also reflected in their lipid profile. Only 23% of the women
had a LDL-C<1.8mmol/L (70mg/dL) compared to 32% in men. This
confirms observations made in EUROASPIRE IV [24] and are congruent
with the observation that women with CHD are less likely to receive
state-of the art evidence-based treatment than men [42,43]. One way to
improve the secondary prevention, including optimal LDL-C control in
female patients would be to incorporate them in multidisciplinary
cardiac rehabilitation programs, presently less frequently prescribed to
women compared to men [44]. Another interesting finding is that on
average young compared to older patients have more elevated levels of
TC, LDL-C, non-HDL-C and TG and low levels of HDL-C. The reason
might be that their physicians underestimate their actual CV risk and
that they are less well informed on their ideal lipid target levels [45].
4.4. Physician inertia
It is worrying that the proportion of patients without LLT in EUR-
OASPIRE V had increased from 12% at the time of hospital discharge to
16% about one year later and that the proportion on high-intensity LLT
had decreased from 58 to 50%. The reasons why practitioners often
prefer low/moderate intensity instead of high-intensity LLT are com-
plex. It is reasonably influenced by the fear of adverse effects with
confusing information on side effects of statins as a contributory factor.
Recent observations on the safety of attaining even very low levels of
LDL-C [19] should re-assure physicians and together with the greater
gain that can be achieved in terms of secondary prevention all this
should be an incentive to prescribe high-intensity LLT in almost all
coronary patients and in the maximal tolerated dose if necessary to
achieve the LDL-C target.
4.5. Concluding remarks
The results of the EUROASPIRE V survey clearly demonstrate that
most patients with established coronary artery disease have suboptimal
lipid management and, most worrisome, LDL-C levels far from those,
based on very solid evidence, recommended by available guidelines.
The causes are multiple and in an immediate need of professional
strategies aiming at lifestyle changes and adequate use of available LLT
adapted to the need of the individual patient. Among such strategies the
present data strongly underlines the need for improved education of the
profession and the patients and a structured care according to principles
that are well established, however, less well put in place. The striking
variability between countries and centers with several examples of well
managed patients serves as evidence that the present conditions can be
improved.
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